


Stabilis



Bumetanide



Noms commerciaux

Bumexlex	Vénézuela
Bumetanide	Etats Unis d'Amérique
Burinex	Autriche, Belgique, Danemark, Egypte, France, Grèce, Luxembourg, Malaisie, Norvège, Pays bas, Suède
Diunide	Egypte
Edemex	Egypte
Miccil	Mexique



Stabilité des solutions

PVC		0,02 & 2 mg/ml	23°C-25°C		72			42



Stabilité en mélange

		0,12 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4	813
		0,0417 mg/ml	2-8°C		Scopolamine hydrobromide : 0,0052 mg/ml	18	4691
		0,125 mg/ml	2-8°C		Scopolamine hydrobromide : 0,0312 mg/ml	18	4691



Facteur influençant la stabilité

				3684
--	--	--	--	------



Compatibilités

				
		Bumetanide : 0.04 mg/ml Amifostine : 10 mg/ml		3
		Bumetanide : 0,2 mg/ml Amiodarone hydrochloride : 3 mg/ml		4698
		Bumetanide : 0.04 mg/ml Aztreonam : 40 mg/ml		99
		Bumetanide : 0.04 mg/ml Bivalirudin : 5 mg/ml		1713
		Bumetanide : 0,04 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Bumetanide : 0.04 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml	RL	2269
		Bumetanide		42
		Bumetanide : 0.04 mg/ml Allopurinol sodium : 3 mg/ml		307
		Bumetanide : 0.04 mg/ml Amifostine : 10 mg/ml		3
		Bumetanide : 0.25 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Bumetanide : 0.25 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Bumetanide : 0,04 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Bumetanide : 0,04 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Bumetanide : 0,04 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Bumetanide : 0.04 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Bumetanide : 0.04 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Bumetanide		3684
		Bumetanide : 0.25 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Bumetanide : 0.04 mg/ml		301
		Bumetanide		3653
		Bumetanide : 0.25 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Bumetanide : 0.04 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Bumetanide : 0.04 mg/ml Cladribine : 0.015 mg/ml		1496
		Bumetanide : 0.04 mg/ml Cladribine : 0.5 mg/ml		1496

		Bumetanide : 0.04 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Bumetanide : 0.25 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Bumetanide : 0.25 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
		Bumetanide : 0.04 mg/ml Docetaxel : 0.9 mg/ml		1754
		Bumetanide : 0,04 mg/ml Doripenem : 5 mg/ml		2262
		Bumetanide : 0,04 mg/ml Doripenem : 5 mg/ml		2262
		Bumetanide : 0,25 mg/ml Eravacycline : 0,6 mg/ml		4434
		Bumetanide : 0.04 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Bumetanide : 0.04 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Bumetanide : 0.04 mg/ml Filgrastim : 30 µg/ml		244
		Bumetanide : 0,006 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Bumetanide : 0.25 mg/ml Fosfomycin : 30 mg/ml		4055
		Bumetanide : 0,006 mg/ml Furosemide : 1 mg/ml		1232
		Bumetanide : 0.04 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Bumetanide : 0,25 mg/ml		4507
		Bumetanide : 0.04 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Bumetanide : 0.04 mg/ml		1415
		Bumetanide : 0.25 mg/ml Fosfomycin : 30 mg/ml		4055
		Bumetanide : 0.04 mg/ml Hetastarch : 60 mg/ml		1721
		Bumetanide : 0,25 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Bumetanide : 0,25 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Bumetanide : 0.25 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Bumetanide : 0.25 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Bumetanide : 0.5 mg/ml Lorazepam : 0.33 mg/ml		186
		Bumetanide : 0.04 mg/ml Melfalan : 0.1 mg/ml		169
		Bumetanide : 0.04 mg/ml Micafungin : 1.5 mg/ml		2108
		Bumetanide : 0.5 mg/ml Midazolam hydrochloride : 5 mg/ml		186

		Bumetanide Milrinone lactate		4987
		Bumetanide		3653
		Bumetanide : 0.5 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Bumetanide : 0,25 mg/ml Milrinone lactate : 1 mg/ml		4506
		Bumetanide : 0.25 mg/ml Morphine sulfate : 1 mg/ml		62
		Bumetanide Nesiritide		5048
		Bumetanide : 0.5 mg/ml Ofloxacin : 5 mg/ml		2139
		Bumetanide : 0.1 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Bumetanide : 0,04 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Bumetanide : 0.04 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Bumetanide : 0.25 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Bumetanide : 0.04 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Bumetanide : 0.25 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Bumetanide : 0.04 mg/ml Propofol : 10 mg/ml		300
		Bumetanide : 0.04 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Bumetanide : 0,25 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Bumetanide : 0.25 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Bumetanide : 0.04 mg/ml Teniposide : 0.1 mg/ml		905
		Bumetanide : 0.04 mg/ml Thiotepa : 1 mg/ml		249
		Bumetanide : 0.04 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Voie d'administration





Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
42	Revue	Cornish LA, Montgomery PA, Johnson CE. Stability of bumetanide in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 422-423.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.

301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.

2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2139	Revue	Serrurier C, Chenot ED, Vigneron J, May I, Demor? B. Assessment of injectable drug's administration in two intensive care units and determination of potential physico-chemical incompatibilities. EJHP Science 2006 ; 12,5: 96-99.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocartil with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3653	Laboratoire	Bumétanide (Burinex®) - Résumé des caractéristiques du produit Laboratoire Léo 2013
3684	Laboratoire	Bumétanide (Burinex®) - Résumé des caractéristiques du produit Laboratoire Léo 2012
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4506	Revue	Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C. Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,23:1938-1940.

4507	Revue	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4691	Revue	Catry E, Colsoul ML, Closset Me, Hubert J, Soumoy L, Bihin B, Thiry E, Jamart J, Hecq JD, Galanti L. Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine. Int J Pharm Compound 2022 ;26,3:248-254
4698	Revue	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022 ; 7(1): 20220002
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4987	Laboratoire	MILRINONE TILLOMED 1 mg/mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit. TILLOMED PHARMA GMBH 2024
5048	Laboratoire	NATRECOR® (nesiritide) lyophilized powder for intravenous use - Highlights of prescribing information. 2012



Dictionnaire

	Diurétique		injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	Glucose 5%		Lumière
	Heure		Stabilité en mélange
	Solvant		Molécule
	Verre		Seringue polypropylène
	Chlorure de sodium 0,9%		Non précisée
	Jour		Facteur influençant la stabilité
	Chlorure de sodium 3%		Provoque
	Précipitation		Compatibilités
	Compatible	RL	Ringer lactate
	Précipitation immédiate		Incompatible
	Nutrition parentérale (mélange binaire)		NaCl 0,9% + bactériostatique
	Changement de couleur		Turbidité immédiate
	Nutrition parentérale (mélange ternaire)		Solvant spécifique
	Turbidité en 15 minutes		Aucun
	Incompatibilité non précisée		Précipitation en 1 heure
	Voie d'administration		Intraveineuse
	Perfusion intraveineuse		Intramusculaire
	Bibliographie		Dictionnaire